Targeted Drug Delivery Device Market Size to Hit 2,153 billion by 2035 | Exclusive Report by Roots Analysis

The pharmaceutical industry is increasingly moving towards biologics from traditional small molecule drugs. This is primarily because of the specificity and efficacy of biologics that makes them proficient in treating complex diseases. Since, it has become increasingly popular because it offers many benefits still biologics poses various challenges, such as drug delivery-related complications along with immunogenicity.

To overcome these challenges, the pharmaceutical industry is focusing on the development of targeted drug delivery devices that will improve the therapeutic safety index and enhance the delivery of therapies to the targeted site. Targeted drug delivery device enables the administration of drugs to specific areas, thereby enhancing efficacy and reducing systemic toxicity. Site-specific drug delivery needs are one of the factors that push forward newer innovative drug delivery technologies and devices.

Considering that biologics pose an inherent delivery challenge, there is a ongoing need for targeted drug delivery devices. Therefore, the companies are actively engaged in manufacturing targeted drug delivery devices that can optimize drug efficacy and safety.

The global targeted drug delivery device market size is estimated to be USD 427 million in 2026 and is expected to reach USD 2,153 million by 2035, growing at a CAGR of 19.7% during the forecast period, till 2035.

By Type of Device, Cannula are anticipated to capture the largest share of the global market

The large share of this market is primarily attributed to the ability of cannulas to deliver higher drug concentration directly at the targeted site, while reducing exposure to healthy tissues.

By Target Organ, Breast segment is anticipated to capture the largest share of the global market

The targeted drug delivery devices delivering drugs directly to the breast capture the highest share. This can be attributed to the rising incidence rate of breast cancer across the globe. This high incidence rate has piqued the interest of researchers to develop more effective treatment options.

By Type of Therapy Delivered, Immunotherapies are anticipated to capture the largest share of the global market

Presently, targeted drug delivery devices designed for the delivery of immunotherapies capture highest share. This can be attributed to the fact that immunotherapies are increasingly preferred in cancer treatment due to their ability to harness the body's immune system to fight tumors.

By Route of Administration, Intratumoral route is anticipated to capture the largest share of the global market

Targeted drug delivery devices administering drugs through intratumoral route captures the largest share. This can be attributed to the fact that drugs delivered intratumorally tend to have prolonged retention within the tumor cells.

By Therapeutic Area, Oncological Disorder is anticipated to capture the highest share of the global market

Targeted drug delivery devices for oncological disorders segment is likely to capture highest market share. This can be attributed to rising prevalence of cancer related indications.

Regional Analysis

North America captures the majority share of the market, and the trend is unlikely to change in the foreseen future. This can be attributed to the regions robust healthcare infrastructure, which facilitates the development and distribution of advanced drug delivery systems. Additionally, substantial investments in research and development from both public and private sectors is contributing to the market's growth potential.

Key Market Players

Alcyone Lifesciences

Algorae Pharmaceuticals

BioCradia

ClearPoint Neuro

Gloriana Therapeutics

Mercator MedSystems

Neurotech Pharmaceuticals

Novartis

OncoSec

PharmaCyte Biotech

PulseSight Therapeutics

Renishaw

Silexion Therapeutics

SmartCella

Key Segments

Based on research, Roots Analysis has segmented the Targeted Drug Delivery Device Market into Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area and Key Geographical Regions.

by Type of Device

Catheters

Cannulas

Others

by Target Organ

Brain

Breast

Eyes

Heart

by Type of Type Therapy Delivered

Cell Therapies

Gene Therapies

Immunotherapies

by Route of Administration

Intratumoral

Transendocardial

Others

by Therapeutic Area

Cardiovascular Disorders

Oncological Disorders

Ophthalmic Disorders

Neurological Disorders

by Key Geographical Region

North America

Europe

Asia-Pacific

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: sales@rootsanalysis.com